Abstract Title:

Comparison of adverse drug reactions with donepezil versus memantine: analysis of the French Pharmacovigilance Database.

Abstract Source:

Therapie. 2010 May-Jun;65(3):255-9. Epub 2010 Aug 11. PMID: 20699079

Abstract Author(s):

Samy Babai, Pascal Auriche, Hervé Le-Louët

Article Affiliation:

Centre Régional de Pharmacovigilance, Hôpital Henri Mondor, Créteil, France. [email protected]

Abstract:

BACKGROUND: Since donepezil and memantine are currently used for treating Alzheimer's disease, it is interesting to analyse, reassess and compare their safety profile in order to promote a better use.

METHODS: All spontaneous reports of suspected serious adverse drug reactions with donepezil alone and with memantine alone recorded in the French Pharmacovigilance Database during 6 years were retrospectively analysed.

RESULTS: The most frequent adverse drug reactions with donepezil alone and memantine alone were respectively: bradycardia (10% versus 7%), weakness (5% versus 6%) and convulsions (4% versus 3%).

CONCLUSION: The most adverse drug events with donepezil and with memantine are associated with elderly people, even if they do not receive any other treatment. Donepezil and memantine have an acceptable safety profile but physicians should take special care when they prescribe any drug known to cause bradycardia or to reduce the epileptogenic threshold.

Print Options


This website is for information purposes only. By providing the information contained herein we are not diagnosing, treating, curing, mitigating, or preventing any type of disease or medical condition. Before beginning any type of natural, integrative or conventional treatment regimen, it is advisable to seek the advice of a licensed healthcare professional.

© Copyright 2008-2024 GreenMedInfo.com, Journal Articles copyright of original owners, MeSH copyright NLM.